Apogee Therapeutics (APGE) Liabilities and Shareholders Equity (2022 - 2026)

Apogee Therapeutics (APGE) has reported Liabilities and Shareholders Equity for 5 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 81.14% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $3.5 billion (up 15.42% YoY), while the FY2025 annual figure was $937.1 million, up 24.3% from the prior year.
• Liabilities and Shareholders Equity advanced to $1.3 billion in Q1 2026 per APGE's latest filing, from $937.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.3 billion in Q1 2026 and bottomed at $130.7 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $653.4 million across 5 years, with a median of $714.2 million in 2025.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 512.75% — and 2025, when it decreased 19.34%.
• Apogee Therapeutics' Liabilities and Shareholders Equity stood at $152.1 million in 2022, then soared by 163.99% to $401.4 million in 2023, then soared by 87.83% to $754.0 million in 2024, then advanced by 24.3% to $937.1 million in 2025, then surged by 38.04% to $1.3 billion in 2026.
• Business Quant data shows APGE's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $937.1 million in Q4 2025, and $626.2 million in Q3 2025.